CN101912356A - 一种氨曲南/精氨酸药物组合物脂微球注射剂 - Google Patents
一种氨曲南/精氨酸药物组合物脂微球注射剂 Download PDFInfo
- Publication number
- CN101912356A CN101912356A CN 201010241312 CN201010241312A CN101912356A CN 101912356 A CN101912356 A CN 101912356A CN 201010241312 CN201010241312 CN 201010241312 CN 201010241312 A CN201010241312 A CN 201010241312A CN 101912356 A CN101912356 A CN 101912356A
- Authority
- CN
- China
- Prior art keywords
- aztreonam
- arginine
- medicinal composition
- injection
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 title claims abstract description 92
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 title claims abstract description 92
- 229960003644 aztreonam Drugs 0.000 title claims abstract description 92
- 239000004475 Arginine Substances 0.000 title claims abstract description 56
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 239000004005 microsphere Substances 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002347 injection Methods 0.000 title claims abstract description 33
- 239000007924 injection Substances 0.000 title claims abstract description 33
- 150000002632 lipids Chemical class 0.000 title claims abstract description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 38
- 150000008064 anhydrides Chemical class 0.000 claims abstract description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 19
- 239000000194 fatty acid Substances 0.000 claims abstract description 19
- 229930195729 fatty acid Natural products 0.000 claims abstract description 19
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 19
- 239000011780 sodium chloride Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 235000011572 Pyrus ussuriensis Nutrition 0.000 claims description 18
- 244000173166 Pyrus ussuriensis Species 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 239000007921 spray Substances 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 8
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- 235000009697 arginine Nutrition 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 31
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 11
- 229930064664 L-arginine Natural products 0.000 description 11
- 235000014852 L-arginine Nutrition 0.000 description 11
- 239000012535 impurity Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000007142 ring opening reaction Methods 0.000 description 4
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102413123A CN101912356B (zh) | 2010-08-02 | 2010-08-02 | 一种氨曲南/精氨酸药物组合物脂微球注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102413123A CN101912356B (zh) | 2010-08-02 | 2010-08-02 | 一种氨曲南/精氨酸药物组合物脂微球注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101912356A true CN101912356A (zh) | 2010-12-15 |
CN101912356B CN101912356B (zh) | 2012-01-11 |
Family
ID=43320114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102413123A Expired - Fee Related CN101912356B (zh) | 2010-08-02 | 2010-08-02 | 一种氨曲南/精氨酸药物组合物脂微球注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101912356B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102058545A (zh) * | 2010-12-24 | 2011-05-18 | 石药集团中诺药业(石家庄)有限公司 | 一种注射用美罗培南冻干制剂及其制备方法 |
CN102119924A (zh) * | 2011-01-24 | 2011-07-13 | 山东鲁抗立科药物化学有限公司 | 单分散纳米氨曲南脂质体制剂及其制备方法 |
CN102145001A (zh) * | 2011-01-24 | 2011-08-10 | 山东鲁抗立科药物化学有限公司 | 稳定的氨曲南组合物及其制备方法 |
CN104856958A (zh) * | 2014-02-21 | 2015-08-26 | 海南灵康制药有限公司 | 氨曲南特种超细粉体制剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6422874A (en) * | 1987-07-01 | 1989-01-25 | Squibb & Sons Inc | Amorphos aztreonum |
WO2005007132A1 (en) * | 2003-07-03 | 2005-01-27 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
US20060088592A1 (en) * | 2004-04-28 | 2006-04-27 | Seung-Ho Choi | Oral formulation for delivery of poorly absorbed drugs |
CN101249074A (zh) * | 2008-04-09 | 2008-08-27 | 海南灵康制药有限公司 | 氨曲南脂质体冻干制剂及其制备方法 |
-
2010
- 2010-08-02 CN CN2010102413123A patent/CN101912356B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6422874A (en) * | 1987-07-01 | 1989-01-25 | Squibb & Sons Inc | Amorphos aztreonum |
WO2005007132A1 (en) * | 2003-07-03 | 2005-01-27 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
EP1641436A1 (en) * | 2003-07-03 | 2006-04-05 | Corus Pharma Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
US20060088592A1 (en) * | 2004-04-28 | 2006-04-27 | Seung-Ho Choi | Oral formulation for delivery of poorly absorbed drugs |
CN101249074A (zh) * | 2008-04-09 | 2008-08-27 | 海南灵康制药有限公司 | 氨曲南脂质体冻干制剂及其制备方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102058545A (zh) * | 2010-12-24 | 2011-05-18 | 石药集团中诺药业(石家庄)有限公司 | 一种注射用美罗培南冻干制剂及其制备方法 |
CN102058545B (zh) * | 2010-12-24 | 2012-07-25 | 石药集团中诺药业(石家庄)有限公司 | 一种注射用美罗培南冻干制剂及其制备方法 |
CN102119924A (zh) * | 2011-01-24 | 2011-07-13 | 山东鲁抗立科药物化学有限公司 | 单分散纳米氨曲南脂质体制剂及其制备方法 |
CN102145001A (zh) * | 2011-01-24 | 2011-08-10 | 山东鲁抗立科药物化学有限公司 | 稳定的氨曲南组合物及其制备方法 |
CN102119924B (zh) * | 2011-01-24 | 2012-09-05 | 山东鲁抗立科药物化学有限公司 | 单分散纳米氨曲南脂质体制剂及其制备方法 |
CN104856958A (zh) * | 2014-02-21 | 2015-08-26 | 海南灵康制药有限公司 | 氨曲南特种超细粉体制剂及其制备方法 |
CN104856958B (zh) * | 2014-02-21 | 2016-07-20 | 海南灵康制药有限公司 | 一种氨曲南制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101912356B (zh) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101415395B (zh) | 酪蛋白纳米粒子 | |
CN101912356B (zh) | 一种氨曲南/精氨酸药物组合物脂微球注射剂 | |
WO1990003781A1 (fr) | Composition pharmaceutique contenant un compose actif hydrophile, traite par un acide organique et encapsule dans un liposome | |
US6001870A (en) | Nasopharynx administration of mupirocin for prophylactic treatment of recurrent otitis media | |
CN1679470A (zh) | 用于化妆品的含海藻糖和透明质酸组合物及其制备方法 | |
US6156792A (en) | Calcium mupirocin non-aqueous nasal spray for otitis media or for recurrent acute bacterial sinusitis | |
MX2010006914A (es) | Sistema de suministro de farmaco para la administracion de substancias farmaceuticamente activas pobremente solubles en agua. | |
WO2008080369A1 (fr) | Composition liposomale stable | |
CN108653004A (zh) | 一种具有多重保湿舒缓修护的组合物及其制备方法 | |
CN101773469B (zh) | 氨曲南/精氨酸药物组合物混悬注射剂 | |
CN101642448B (zh) | 纳米青蒿琥酯胶囊的制备工艺 | |
EP2074988B1 (en) | Sustained release composition and manufacturing method thereof | |
CN103830181A (zh) | 一种多西他赛冻干脂质体及其制备方法 | |
CN101804060B (zh) | 一种头孢曲松钠/他唑巴坦钠药物组合物微球注射剂 | |
CN102119924B (zh) | 单分散纳米氨曲南脂质体制剂及其制备方法 | |
CN104856958B (zh) | 一种氨曲南制剂及其制备方法 | |
CN101209244A (zh) | 一种乙酰吉他霉素微囊型粉末的生产方法 | |
CN101890014B (zh) | 一种哌拉西林钠舒巴坦钠药物组合物脂质体注射剂 | |
CN113398072A (zh) | 注射用头孢唑林钠及其制备方法 | |
CN101836960B (zh) | 一种头孢孟多酯钠/无水碳酸钠药物组合物微球注射剂 | |
CN101890015B (zh) | 一种哌拉西林钠他唑巴坦钠药物组合物脂质体注射剂 | |
CN108420801A (zh) | 一种抗运动疲劳的白藜芦醇固体脂质纳米粒及其制备方法 | |
CN110396102A (zh) | 头孢西丁钠药物制剂在经***子宫切除、腹腔子宫切除、剖腹(宫)产术前预防感染应用 | |
RU2000100955A (ru) | Порошкообразные композиции униламеллярных липосом | |
CN102772356A (zh) | 基于紫杉醇的小分子水凝胶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN LINGKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG MING Effective date: 20130724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130724 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd. Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601 Patentee before: Wang Ming |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120111 Termination date: 20160802 |